"By blocking blood vessels generated to proliferate cancer, cancer is starved to death.There is a drug that realizes the theory of a professor at Harvard University in the U.S., who caused a "sensation" in the 1970s. Avastin, a Vascal Endothermic Growth Factor (VEGF) inhibitor, which is also considered a good partner for immuno-cancer drugs. It's the first anti-VEGF event to surpass 100 billion won.

Avastin was launched when Genentech in the United States was interested in angiogenesis research and discovered VEGF and genes. Avastin has greatly succeeded along with new antibody drugs such as Rituxan and Herceptin. After Avastin's approval, Roche completely acquired Genentec. Avastin received a lot of